Data from EMC - Curated by Toby Galbraith - Last updated 09 August 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Neuropathic pain
Pregabalin Pfizer is indicated for the treatment of peripheral and central neuropathic pain in adults.

Epilepsy
Pregabalin Pfizer is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Generalised anxiety disorder
Pregabalin Pfizer is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Bedwetting

Essential screening, diagnosis and best strategies to manage bedwetting

Visit Bedwetting


Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients

Visit Oral Anticoagulation Reversal


Related Content

More information

Category Value
Agency product number EMEA/H/C/003880
Orphan designation No
Date First Approved 10-04-2014
Type Medicinal product subject to medical prescription
Marketing authorisation holder Pfizer Limited